Article
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Current opinion in biotechnology - 1 Apr 2021
Leca Julie, Fortin Jerome, Mak Tak W
Abstract excerpt
Mutations in the genes encoding isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are key drivers of diverse cancers, including gliomas and hematological malignancies. IDH mutations cause neomorphic enzymatic activity that results in the production of the oncometabolite 2-hydroxyglutarate (2-HG). In addition to 2-HG's well-known effects on tumor cells themselves, it has become increasingly clear that 2-HG directly...
Topics
Join the communities discussing this publication.